HWM
CGTX icon

Hohimer Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Hohimer Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-225,000
Closed -$410K – 222
2024
Q1 		$410K Buy
+225,000
New +$465K 0.1% 168

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Hohimer Wealth Management's CGTX Position: Q2 2024 in Review

Hohimer Wealth Management sold out of Cognition Therapeutics (CGTX) in Q2 2024, closing a stake of 225,000 shares — an estimated $410K sold.

Hohimer Wealth Management first reported a position in CGTX in Q1 2024 and held it in 1 quarter. The position peaked at $410K in Q1 2024. 46 funds tracked by Wall St. Rank hold CGTX as of Q2 2024.

  • Hohimer Wealth Management reported no remaining Cognition Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Hohimer Wealth Management sold 225,000 Cognition Therapeutics shares in Q2 2024, an estimated $410K.
  • Hohimer Wealth Management first reported a position in Cognition Therapeutics in Q1 2024 and held it in 1 quarter.
  • Hohimer Wealth Management's Cognition Therapeutics position peaked at $410K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2024.

Based on Hohimer Wealth Management's 13F filing for Q2 2024, filed 2 Aug 2024.